Astroglial dysfunction in models of CDKL5 deficiency disorder

CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy typically caused by loss of function variants in the gene encoding the X-linked serine–threonine kinase CDKL5. CDKL5 is highly expressed in the brain during development, and key neuronal functions of the kinase include cytoskeletal organisation and synaptic stability. However, at present, little is known about the function of astroglia in CDD. Given the importance of these cells in synaptic development and homeostasis, as well as dysfunction in other epileptic diseases, it was hypothesised that astrocytes may contribute to CDD pathology. Induced pluripotent stem cells harbouring a CDKL5 loss-of-function mutation (and isogenic controls) were derived from CDD patient fibroblasts and differentiated into astrocytes (iAstros). Analysis of iAstros revealed transcriptomic, proteomic and functional dysregulation in CDKL5-mutant iAstros relating to water transport and immunological function, including a diminished response to TNFα stimulation. Moreover, iAstros showed increased branching and reduced phosphorylation of the known CDKL5 target end-binding protein 2 (EB2) - indicative of disrupted cytoskeletal regulation in a manner similar to CDKL5-null neurons. Finally, we report proof-of-concept of novel in vitro models of CDD. CDKL5 was knocked down in adult and foetal human organotypic brain slices through transduction with an AAV encoding a novel CDKL5 shRNA. Slices transduced with the CDKL5 shRNA displayed a trending increase in spontaneous network activity compared to those transduced with a scrambled control, demonstrating the functionality of this model. Importantly, interrogation of these models revealed dysregulation of key astrocytic proteins congruent with the human glial stem cell model. Consequently, this study describes the generation of novel human models of CDD and initial findings of astrocytic dysfunction – paving the way for novel discovery and therapeutic intervention.

Authors

Institutions

Publication Details

Journal
Frontiers in Cellular Neuroscience
Published
2026-10-30
DOI
https://doi.org/10.3389/fncel.2026.1934251
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Astroglial dysfunction in models of CDKL5 deficiency disorder

Christopher J. A. Cowie, Maria Kinali, Faye McLeod, Nicholas D. Mazarakis et al.
Frontiers in Cellular Neuroscience
Epilepsy research and treatment
article

Astroglial dysfunction in models of CDKL5 deficiency disorder

Christopher J. A. Cowie, Maria Kinali, Faye McLeod, Nicholas D. Mazarakis, Ceri A. Pickering, Gavin John Clowry, Adriana Bakoulina, Zhi Yi Alicia Seet, Alishba Saleemi, Yimiao Wu, Angeliki Pantziarou, Antriksh A. Goyal
article en

Abstract

CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy typically caused by loss of function variants in the gene encoding the X-linked serine–threonine kinase CDKL5. CDKL5 is highly expressed in the brain during development, and key neuronal functions of the kinase include cytoskeletal organisation and synaptic stability. However, at present, little is known about the function of astroglia in CDD. Given the importance of these cells in synaptic development and homeostasis, as well as dysfunction in other epileptic diseases, it was hypothesised that astrocytes may contribute to CDD pathology. Induced pluripotent stem cells harbouring a CDKL5 loss-of-function mutation (and isogenic controls) were derived from CDD patient fibroblasts and differentiated into astrocytes (iAstros). Analysis of iAstros revealed transcriptomic, proteomic and functional dysregulation in CDKL5-mutant iAstros relating to water transport and immunological function, including a diminished response to TNFα stimulation. Moreover, iAstros showed increased branching and reduced phosphorylation of the known CDKL5 target end-binding protein 2 (EB2) - indicative of disrupted cytoskeletal regulation in a manner similar to CDKL5-null neurons. Finally, we report proof-of-concept of novel in vitro models of CDD. CDKL5 was knocked down in adult and foetal human organotypic brain slices through transduction with an AAV encoding a novel CDKL5 shRNA. Slices transduced with the CDKL5 shRNA displayed a trending increase in spontaneous network activity compared to those transduced with a scrambled control, demonstrating the functionality of this model. Importantly, interrogation of these models revealed dysregulation of key astrocytic proteins congruent with the human glial stem cell model. Consequently, this study describes the generation of novel human models of CDD and initial findings of astrocytic dysfunction – paving the way for novel discovery and therapeutic intervention.

Frontiers in Cellular NeuroscienceVol. 20
Royal Victoria Infirmary (GB), HCA Healthcare (US), The Portland Hospital (GB), Imperial College London (GB), Newcastle University (GB)
Good health and well-being
Openalex Percentile: Top 12%
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon